Anti-PD-1/PD-L1 antibody (investigational)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-PD-1/PD-L1 antibody (investigational), covering 2025-11-18 to 2025-11-18. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer [Phase 1]